Fortress Biotech, Inc. Operating Income Loss

• Fortress Biotech, Inc. showed an increase of +36.4% in Operating Income Loss from 2024 to 2025.
• This data is from Fortress Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Fortress Biotech, Inc.'s Operating Income Loss has declined by 2,587.4%.
• Historical annual values: Fiscal year 2025: -$70.22 million | Fiscal year 2024: -$110.38 million | Fiscal year 2023: -$142.34 million | Fiscal year 2022: -$203.56 million | Fiscal year 2021: -$188.54 million | Fiscal year 2020: -$94.27 million | Fiscal year 2019: -$110.82 million | Fiscal year 2018: -$120.00 million | Fiscal year 2017: -$89.80 million | Fiscal year 2016: -$65.71 million | Fiscal year 2015: -$50.53 million | Fiscal year 2014: -$20.65 million | Fiscal year 2013: -$35.78 million | Fiscal year 2012: -$27.18 million | Fiscal year 2011: -$35.04 million | Fiscal year 2010: -$9.24 million | Fiscal year 2009: -$2.61 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026